Company intelligence / Profile preview

NeoMatrix Therapeutics

Stony Brook, New York, United Statesneomatrixtx.com ↗

Ownership: Private
Development stage: Phase 2

Overview

NeoMatrix Therapeutics develops novel bioactive peptides that prevent the progression of tissue injury after severe burns. Their lead candidate, NMT-cP12, has entered a Phase 2a clinical trial with promising results in reducing healing time and scarring. The second candidate, NMT-cNP8, has completed Phase 1 trials and shows antimicrobial properties suitable for topical application. Both candidates have demonstrated efficacy in preclinical models and early human studies.[1][2]

Therapeutic areas: OtherDermatology
Modalities: Bioactive peptides (notably NMT-cP12 and NMT-cNP8)[1][2][5]
Industry: Biotech

Drug pipeline

3 assets

cP12

2 more assets in the full pipeline.

Partnerships

U.S. Army Medical Research funding since at least 2012 for both lead programs; no major pharma partnerships disclosed.[2]

Beyond the preview

Go deeper on NeoMatrix Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeoMatrix Therapeutics.